Delivery Order SPE2DB20D1109-SPE2DB25FP60B
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,592.44 to AmerisourceBergen Drug Corp for Nucynta ER 50 mg tablets (60-count supply) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $2,944.08 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 100 mg tablets (60-count packages) with a completion date of August 11, 2025. This competitively awarded, non-set-aside contract operates under a firm fixed price arrangement and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,899.74 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 150 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order valued at $1,367.15 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 150 mg tablets (60-count) on August 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at the awardee's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Department's Medical Supply Chain awarded a delivery order valued at $10,441.56 to AmerisourceBergen Drug Corp for Nucynta Tabs 50mg on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $7,070.28 to AmerisourceBergen Drug Corp for Nucynta Tabs 100mg, a prescription pain management medication. This competitively awarded, firm fixed-price contract was issued on August 8, 2025, with an ultimate completion date of August 11, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on August 1, 2025, for the supply of Nucynta ER Tabs 150mg. This competitive, non-set-aside contract has a ceiling value of $6,849.48 and is structured as a firm fixed price delivery order with an ultimate completion date of August 4, 2025. The award is issued under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $13,932.13 for Nucynta Tabs 75mg, a pain management pharmaceutical product. This firm fixed-price delivery order, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a competitive procurement with no set-aside designation. The award is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $2,244.18 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 250 mg tablets (60-count) on July 31, 2025, with completion targeted for August 1, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award carries no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Nucynta ER 50 mg tablets (60-count), with a contract ceiling value of $1,398.37. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award to the contractor. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP60BDelivery Order
The Defense Logistics Agency awarded a $2,208.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Nucynta ER 100 mg, with an ultimate completion date of August 20, 2025. The award, issued on August 19, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The place of performance is located in Conshohocken, PA. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and extending through December 2026. This prime contract vehicle supports military healthcare programs globally by providing a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains. The company's federal contract portfolio demonstrates consistent capability to fulfill open competition requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, positioning it as a key provider within DLA's pharmaceutical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/19/25 |